Business Wire

NATIONAL-TSING

12.5.2020 11:02:12 CEST | Business Wire | Press release

Share
Taipei School of Economics and Political Science Established at NTHU with US$100 Million Donation

On May 9 National Tsing Hua University entered into an agreement to jointly establish the Taipei School of Economics and Political Science (TSE) together with the TSE Foundation, which was set up with a US$100 million donation from entrepreneur Lin Chen-hai, the founder of the Pau Jar Group. The mission of the TSE will be to provide world-class education in economics, international politics, and public affairs, with Asia as the center of gravity, and will soon begin recruiting top-notch faculty from around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005343/en/

At the signing ceremony, TSE Foundation chairman Huang Huang-hsiung said that the TSE will be located on the NTHU campus, and that this type of cooperation between the public and private sectors is a new first in the history of higher education in Taiwan.

Also present at the ceremony was Minister of Education Pan Wen-chung, who said that the establishment of the TSE is undoubtedly a new milestone for higher education in Taiwan. NTHU president Hocheng Hong said that the plan for establishing the TSE has already been approved by the Ministry of Education, and that it will soon begin recruiting master’s and doctoral students for the 2021-22 school year, two thirds of whom will be international students, adding that all courses will be taught in English.

Chairman Huang said that the TSE aims to attract outstanding students and world-class faculty, for which purpose he is helping to set up an international advisory committee, which includes four former ministers of education to arrange academic exchanges with such well-known institutions as the London School of Economics(LSE) and the Harvard Kennedy School.

NTHU president Hocheng Hong said that public-private cooperation in education on such a scale is unprecedented, pointing out that Lin’s US$100 million donation is the largest ever made in the field of social science education in Taiwan.

Hocheng asserted that technology is a major factor in all of the most pressing challenges facing humanity, such as food security, environmental preservation, energy, war, and even epidemics, and that any viable solution must take account of technological, political, and economic factors, adding that this was one of the principle motivations for establishing the TSE at National Tsing Hua University.

Hocheng said that the TSE will be the eleventh college at NTHU, and that its multi-disciplinary master’s and doctoral programs will be modeled on those of the LSE. The TSE plans to admit at least ten master’s students for the 2021-22 school year, and in the following school year at least 40 master’s students and ten doctoral students, after which enrollment numbers will gradually increase year by year. During the initial phase, TSE classes will be held in the Innovation Incubation Building on the NTHU campus, until the program’s own building is completed both on campus and in Taipei.

Link:

ClickThru

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye